{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:35:11Z","timestamp":1793392511546,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.pnpbp.2019.109800","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T03:10:50Z","timestamp":1572664250000},"page":"109800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Abnormal C-reactive protein blood levels as a specific biomarker of major depression and non-remission under antidepressants in schizophrenia"],"prefix":"10.1016","volume":"97","author":[{"given":"G.","family":"Fond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Micoulaud-Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Faugere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Faget-Agius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lan\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Richieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cermolacce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2019.109800_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatry. Suppl."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014a new world-wide definition. A consensus statement from the International diabetes federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet. Med."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing\u2014when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0020","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/schbul\/sbw029","article-title":"Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset","volume":"42","author":"Bulzacka","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials","author":"Cho","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.24869\/psyd.2017.459","article-title":"Positive impact of prescribed physical activity on symptoms of schizophrenia: randomized clinical trial","volume":"29","author":"Curcic","year":"2017","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jad.2017.09.004","article-title":"High C-reactive protein levels are associated with depressive symptoms in schizophrenia","volume":"225","author":"Faugere","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0040","article-title":"What does plasma CRP tell us about peripheral and central inflammation in depression?","author":"Felger","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0045","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00213-016-4303-0","article-title":"Medication and aggressiveness in \u201creal world\u201d schizophrenia: current issues and perspectives","volume":"233","author":"Fond","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/schbul\/sbv002","article-title":"The promise of biological markers for treatment response in first-episode psychosis: a systematic review","volume":"41","author":"Fond","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2015.11.017","article-title":"Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set","volume":"191","author":"Fond","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-017-0771-4","article-title":"Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort","author":"Fond","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0070","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-017-0771-4","article-title":"Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort","author":"Fond","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0085","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-017-0847-1","article-title":"Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort","author":"Fond","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0090","article-title":"Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program","author":"Fond","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2015.07.047","article-title":"Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort","author":"Godin","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpsychires.2017.06.008","article-title":"Predictors of rapid high weight gain in schizophrenia: longitudinal analysis of the French FACE-SZ cohort","volume":"94","author":"Godin","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0105","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and blood institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0110","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1038\/npp.2011.132","article-title":"The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis","volume":"36","author":"Hannestad","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/acps.12698","article-title":"Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies","volume":"135","author":"K\u00f6hler","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0125","first-page":"4195","article-title":"Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis","volume":"55","author":"K\u00f6hler","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0130","article-title":"Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies","author":"Lassale","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.psychres.2018.06.062","article-title":"Toward a transdiagnostic tool to evaluate depressive symptoms across mental disorders: validation of the calgary depression rating scale in patients with major depressive disorder","volume":"268","author":"Micoulaud-Franchi","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0140","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-017-0779-9","article-title":"Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset","author":"Rey","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0145","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1176\/appi.ajp.2016.15091228","article-title":"Adjunctive nutraceuticals for depression: a systematic review and meta-analyses","volume":"173","author":"Sarris","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol Consumption--II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addict. Abingdon Engl."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0155","article-title":"The 10-year findings from the fondamental academic center of expertise for Schizophrenia (FACE-SZ): review and recommendations for clinical practice","author":"Sch\u00fcrhoff","year":"2018","journal-title":"L\u2019Encephale"},{"key":"10.1016\/j.pnpbp.2019.109800_bb0160","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","author":"Sommer","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0165","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1348\/014466502760387533","article-title":"The concurrent validity of the Global Assessment of Functioning (GAF)","volume":"41","author":"Startup","year":"2002","journal-title":"Br. J. Clin. Psychol."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0170","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/NDT.S47450","article-title":"Prevalence of metabolic syndrome and its association with depression in patients with schizophrenia","volume":"9","author":"Suttajit","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0175","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/PSY.0000000000000707","article-title":"The association between selective serotonin reuptake inhibitors and Glycemia: a systematic review and meta-analysis of randomized controlled trials","volume":"81","author":"Tharmaraja","year":"2019","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.pnpbp.2019.109800_bb0180","first-page":"1","article-title":"Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder","author":"Wysoki\u0144ski","year":"2014","journal-title":"Nord. J. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461930449X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858461930449X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:49:14Z","timestamp":1759520954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858461930449X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"alternative-id":["S027858461930449X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2019.109800","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormal C-reactive protein blood levels as a specific biomarker of major depression and non-remission under antidepressants in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2019.109800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109800"}}